Buy Cyclophosphamide

Cyclophosphamide

Cyclophosphamide: Generic Medication Overview

Cyclophosphamide is an alkylating chemotherapy agent classified under oncology support medications. It is supplied as an oral pill and commonly available in a 50 mg strength. In the United Kingdom, cyclophosphamide is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug is used primarily in cancer treatment protocols and, in some cases, for severe autoimmune conditions.

How Cyclophosphamide Works in the Body

Cyclophosphamide is a pro-drug that requires metabolic activation. After oral ingestion, liver enzymes (mainly CYP2B6) convert it into active metabolites, including phosphoramide mustard and acrolein.

• Phosphoramide mustard forms covalent bonds with DNA, creating cross-links that prevent DNA replication and trigger cell death.
• Acrolein is a toxic by-product responsible for irritation of the urinary tract; co-administration of the protective agent mesna can neutralise this effect.

The drug’s rapid action on dividing cells makes it effective against malignant tumour cells, while its impact on the immune system underpins its use in certain autoimmune diseases.

Conditions Treated by Cyclophosphamide

Cyclophosphamide is authorised by the MHRA (and by the European Medicines Agency) for a range of oncology and immunology indications, including:

• Breast cancer - as part of combination chemotherapy regimens.
• Non-Hodgkin and Hodgkin lymphoma - both adult and paediatric protocols.
• Acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML).
• Multiple myeloma - often paired with other agents such as dexamethasone.
• Ovarian and endometrial cancers - in adjuvant or recurrent-disease settings.
• Soft-tissue sarcomas - when surgical options are limited.
• Severe autoimmune disorders (e.g., systemic lupus erythematosus, vasculitis) - prescribed when disease-modifying therapies have failed.

Exact dosing and cycle length differ according to disease, patient weight, organ function, and treatment protocol.

Evidence-Based Off-Label Uses

Clinical research has explored additional applications of cyclophosphamide, such as:

• Scleroderma renal crisis - small studies suggest benefit when combined with ACE inhibitors.
• High-risk neuroblastoma - investigational protocols evaluate intensified dosing.

These uses are not approved by the MHRA and should only be pursued under specialist supervision, with careful risk-benefit assessment.

Who Should (Not) Use Cyclophosphamide?

Absolute Contra-indications

• Known hypersensitivity to cyclophosphamide or any of its excipients.
• Pregnancy - classified as Category D; the drug can cause fetal malformations and should be avoided.
• Severe bone-marrow suppression (e.g., absolute neutrophil count < 0.5 × 10⁹/L).
• Active, uncontrolled infections.
• Current bladder carcinoma or a history of severe hemorrhagic cystitis.

Relative Contra-indications

• Renal impairment - dose adjustments required when creatinine clearance < 30 mL/min.
• Hepatic dysfunction - reduced clearance may increase toxicity.
• Advanced age or frailty - increased susceptibility to myelosuppression.
• Concomitant use of live vaccines - immunosuppression may diminish vaccine efficacy.

Special Populations

• Breast-feeding - cyclophosphamide is excreted in milk; cessation of breastfeeding is recommended.
• Pediatrics - dosing is weight-based and strictly supervised by a paediatric oncologist.

If any of the above conditions apply, a thorough evaluation by the treating clinician is essential.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea and vomiting (often mitigated with anti-emetics).
• Alopecia (hair loss) - usually reversible after therapy ends.
• Myelosuppression - decreased white cells, red cells, and platelets; manifests as fatigue, infection risk, and easy bruising.
• Hemorrhagic cystitis - irritative urinary symptoms; prophylactic mesna and adequate hydration reduce risk.
• Mild transient fever, loss of appetite, and taste changes.

Serious Adverse Events

• Severe bone-marrow failure leading to life-threatening infections or bleeding.
• Secondary malignancies (e.g., acute leukaemia) with long-term exposure.
• Cardiotoxicity - rare but possible, especially at high cumulative doses.
• Pulmonary toxicity - interstitial pneumonitis reported in isolated cases.

Patients should seek immediate medical attention for fever > 38 °C, persistent vomiting, severe abdominal pain, or blood in urine.

Drug Interactions

• CYP inducers (e.g., rifampicin, carbamazepine) may lower cyclophosphamide levels, reducing efficacy.
• CYP inhibitors (e.g., fluconazole, erythromycin) can raise plasma concentrations, increasing toxicity risk.
• Live vaccines - should be avoided while on therapy due to immunosuppression.
• Mesna - co-administration protects the bladder from acrolein-mediated damage.

Always disclose all prescription drugs, over-the-counter medicines, supplements, and herbal products to the prescribing clinician.

Food and Lifestyle Interactions

• No major food-drug interactions, but taking the pill with a full glass of water and with food can lessen gastrointestinal irritation.
• Hydration (≥ 2 L/day) is crucial to prevent bladder toxicity.
• Alcohol does not directly interact, yet excessive intake may exacerbate liver toxicity and should be limited.
• Patients should avoid operating heavy machinery if they experience severe fatigue or dizziness.

How to Take Cyclophosphamide

• Formulation: Oral tablets containing 50 mg cyclophosphamide each.
• Administration: Swallow whole with a glass of water; crushing or splitting the tablet may alter absorption.
• Typical Regimens: Treatment is delivered in cycles (e.g., daily for 1-5 days every 3-4 weeks) tailored to the specific disease and patient factors. Exact milligram amounts per day vary widely; the 50 mg tablet is used as a building block within these protocols.
• Missed Dose: If a dose is forgotten, take it as soon as remembered unless the next scheduled dose is due; do not double the dose.
• Overdose: Symptoms may include severe nausea, vomiting, low blood counts, and urinary bleeding. Seek emergency care; supportive measures and, if appropriate, continuous mesna infusion are employed.
• Discontinuation: Sudden cessation is generally safe, but some regimens require a taper to avoid disease flare-ups (particularly in autoimmune indications).

All dosing decisions must be made by the treating oncologist or specialist physician.

Monitoring and Follow-Up

• Complete blood count (CBC) before each cycle to detect myelosuppression.
• Renal function tests (serum creatinine, eGFR) to guide dose adjustments.
• Liver enzymes (ALT, AST, bilirubin) periodically.
• Urinalysis for blood or protein to identify early bladder irritation; adjust mesna or hydration accordingly.
• Cardiac assessment (ECG, echocardiogram) for patients receiving high cumulative doses or with pre-existing heart disease.

Regular clinic visits enable early detection of adverse effects and allow dose modifications.

Storage and Handling

• Keep tablets in their original container, tightly closed, at room temperature (20-25 °C).
• Protect from excess moisture and direct sunlight.
• Do not store in the bathroom or near the kitchen sink.
• Dispose of unused medication according to local pharmacy-take-back programmes or the NHS guidelines for hazardous waste.

Medication-Specific Glossary

Alkylating agent

A class of chemotherapy drugs that add alkyl groups to DNA, causing cross-linking and cell-death.

Myelosuppression

Suppression of bone-marrow activity leading to reduced production of blood cells.

Hemorrhagic cystitis

Inflammation and bleeding of the bladder, often caused by the acrolein metabolite of cyclophosphamide.

Mesna

A protective agent that binds acrolein in the urine, preventing bladder toxicity.

Cyclophosphamide metabolite (phosphoramide mustard)

The active DNA-alkylating component responsible for anticancer effects.

Medical Disclaimer

This article provides educational information about cyclophosphamide and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.